Blockchain Registration Transaction Record

Kairos Pharma Expands Pipeline with CL-741 Acquisition

Kairos Pharma (KAPA) announces mid-year 2026 update, plans to acquire CL-741 from Celyn Therapeutics, and advances ENV-105 trials in prostate and lung cancer. Learn about the company's pipeline and non-dilutive funding.

This news matters because Kairos Pharma's expansion into c-MET inhibition with CL-741 could provide a new treatment option for patients with EGFR-mutated lung cancer, a disease with high unmet need. The company's focus on overcoming drug resistance, particularly through ENV-105 targeting CD105, has the potential to improve outcomes for prostate and lung cancer patients. With over $8 million in non-dilutive funding, Kairos is well-positioned to advance its pipeline, which may lead to more effective therapies and better survival rates for cancer patients.